RS Oncology announces new preclinical data showing that RSO-021 can block and/or reverse the progression of aggressive mesotheliomas, improving drug availability

RS Oncology announces new preclinical data showing that RSO-021 can block and/or reverse the progression of aggressive mesotheliomas, improving drug availability RS Oncology , a clinical-stage biotechnology company developing innovative therapies…

Read MoreRS Oncology announces new preclinical data showing that RSO-021 can block and/or reverse the progression of aggressive mesotheliomas, improving drug availability

Ahead of UN General Assembly, pharmaceutical industry calls attention to need for pandemic preparedness plans to support innovation and equity

Ahead of UN General Assembly, pharmaceutical industry calls attention to need for pandemic preparedness plans to support innovation and equity Ahead of discussions at the United Nations General Assembly (UNGA78),…

Read MoreAhead of UN General Assembly, pharmaceutical industry calls attention to need for pandemic preparedness plans to support innovation and equity

IRLCA and EAD unveil dynamic partnership to shape the future of compliance and technology for the life sciences industry

IRLCA and EAD unveil dynamic partnership to shape the future of compliance and technology for the life sciences industry IRLCA und EAD haben die Grundlage für eine bahnbrechende Zusammenarbeit gelegt, die regulatorische Compliance…

Read MoreIRLCA and EAD unveil dynamic partnership to shape the future of compliance and technology for the life sciences industry

Roche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi therapeutic in development to treat hypertension in patients at high risk of cardiovascular disease

Roche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi therapeutic in development to treat hypertension in patients at high risk of cardiovascular…

Read MoreRoche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi therapeutic in development to treat hypertension in patients at high risk of cardiovascular disease

Bristol Myers Squibb Celebrates a Decade of Its Coast 2 Coast 4 Cancer Cross-Country Bike Ride in Support of the V Foundation for Cancer Research

Bristol Myers Squibb Celebrates a Decade of Its Coast 2 Coast 4 Cancer Cross-Country Bike Ride in Support of the V Foundation for Cancer Research With cancer patients top of…

Read MoreBristol Myers Squibb Celebrates a Decade of Its Coast 2 Coast 4 Cancer Cross-Country Bike Ride in Support of the V Foundation for Cancer Research